IDEXX Laboratories, Inc. 2018 Form 10-K Summary
Business context and reporting period
Form 10-K for the fiscal year ended December 31, 2018, filed February 15, 2019. IDEXX develops diagnostic products, laboratory services, veterinary practice-management software, water-testing products, livestock and dairy diagnostics, and human point-of-care analyzers. The Companion Animal Group (CAG) is the primary business and represented approximately 87% of consolidated revenue. Approximately 39% of revenue came from customers outside the United States.
Financial performance and position
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $2.213 billion | $1.969 billion | +12.4% |
| Gross profit / margin | $1.242 billion / 56.1% | $1.097 billion / 55.7% | Margin +40 bps |
| Operating income / margin | $491.3 million / 22.2% | $413.0 million / 21.0% | +19.0%; margin +120 bps |
| Net income attributable to IDEXX stockholders | $377.0 million | $263.1 million | +43.3% |
| Diluted EPS | $4.26 | $2.94 | +44.9% |
| Cash flow from operations | $400.1 million | $373.3 million | +7.2% |
| Capital expenditures | $115.8 million | $74.4 million | +$41.4 million |
- CAG revenue increased 13.6% to $1.935 billion, including 12.8% organic growth. CAG operating margin increased to 22.2% from 21.3%.
- CAG recurring diagnostic revenue increased 14.0% to $1.655 billion and represented approximately 75% of consolidated revenue. VetLab consumables increased 19.0%, and reference laboratory revenue increased 13.1%.
- Water revenue increased 9.4% to $125.2 million, with operating margin rising to 45.2% from 44.2%.
- LPD revenue increased 1.6% to $130.6 million, while operating margin improved to 14.9% from 12.8%.
- Other revenue declined 3.4% to $22.0 million, and operating margin declined to 16.9% from 21.2%, primarily due to weaker OPTI Medical volumes and higher product costs.
- Cash and cash equivalents were $123.8 million at year-end; 2017 included $284.3 million of marketable securities that were liquidated in 2018.
- Working capital was negative $116.3 million. Total debt was approximately $1.000 billion, consisting of $398.9 million outstanding under the revolving credit facility and $601.3 million of long-term debt.
- Adjusted EBITDA was $603.4 million; gross debt-to-Adjusted EBITDA was 1.67x and net debt-to-Adjusted EBITDA was 1.46x. The company was in compliance with debt covenants.
Material changes versus the prior comparable period
- Revenue growth accelerated from 10.9% in 2017 to 12.4% in 2018, led by CAG recurring diagnostics, installed-base expansion, higher testing volumes, price increases and international growth.
- Operating leverage improved as revenue growth exceeded operating-expense growth, despite continued investment in sales, marketing, research and development, information technology and laboratory capacity.
- Net income benefited from a lower effective tax rate of 17.6%, compared with 30.9% in 2017, primarily because of the reduced U.S. statutory rate under the 2017 Tax Act and the absence of the prior-year transition-tax impact.
- IDEXX adopted the new revenue standard using the modified retrospective method. Reported 2018 revenue was approximately $58.3 million higher, operating income $25.0 million higher and net income $18.1 million higher than under previous U.S. GAAP. Opening retained earnings was reduced by $12.6 million.
- The company introduced the IDEXX 360 volume-commitment program, which increased upfront instrument revenue recognition and created contract assets. Future revenue recognition depends on customer purchases and estimates of rebates, price adjustments and commitments.
- Cash used in financing increased to $597.8 million, driven by $369.3 million of share repurchases and a $256.0 million net repayment of revolving debt. The company repurchased 1.773 million shares for $368.7 million.
- IDEXX acquired a veterinary software business for approximately $25.0 million, including contingent consideration, and invested $5.0 million for a minority interest in a technology company.
Guidance, outlook, commentary, risks and unusual items
- No explicit 2019 revenue, operating-income or EPS guidance is provided in the filing text. Management stated that cash, operating cash flow and available credit should fund operations, capital requirements and anticipated growth for at least the next twelve months.
- Planned 2019 capital expenditures were approximately $160 million to $175 million, including headquarters expansion, German laboratory relocation and expansion, manufacturing, laboratory equipment, software and information-technology infrastructure.
- Management estimated that a stronger U.S. dollar would reduce 2019 revenue by approximately $37 million, operating profit by $4 million and diluted EPS by $0.03, including expected hedging effects. A 1% dollar strengthening was estimated to reduce revenue by approximately $8 million and operating income by approximately $4 million before incremental hedge gains of approximately $2 million.
- The company discontinued development of its in-clinic SNAP Fecal product and recorded a $2.6 million impairment charge for related production equipment.
- Key risks include intense competition and customer consolidation in veterinary markets; reliance on sole- and single-source suppliers; regulatory approvals and compliance; foreign currency exposure; economic sensitivity of veterinary spending; cybersecurity and data-privacy requirements; patent expiration and potential infringement claims; tax audits and uncertain tax positions; and debt covenant or refinancing risk.
- Contractual cash obligations totaled approximately $1.115 billion, including $721.7 million of long-term debt obligations, $106.8 million of operating leases, $284.3 million of purchase obligations and $2.1 million of minimum royalty payments.
- Remaining obligations related to the 2017 Tax Act deemed-repatriation tax were $26.6 million, payable through 2025. Unrecognized tax benefits were $24.2 million at year-end.
- The company reported no goodwill impairment in 2018 and no material pending legal contingency, although management cautioned that litigation outcomes cannot be predicted with certainty. Internal control over financial reporting was judged effective by management and the independent auditor.
Important facts investors should verify
- Reconcile 2018 growth and margins excluding the new revenue standard, including the $58.3 million revenue and $25.0 million operating-income effects.
- Assess the sustainability of CAG recurring revenue growth, consumables utilization, reference-laboratory volumes, price increases and the expanding Catalyst, ProCyte and SediVue installed bases.
- Review the cash economics and future revenue recognition of IDEXX 360, customer loyalty, instrument rebate and reagent-rental programs, including approximately $1.3 billion of estimated future committed-program revenue.
- Evaluate liquidity after planned 2019 capital expenditures, share repurchases and debt obligations, particularly given negative working capital and $398.9 million drawn on the revolving facility.
- Test sensitivity to foreign exchange, interest rates, supplier disruptions, regulatory changes, veterinary-market consolidation and slower pet-owner demand.
- Verify the effect of tax-rate normalization, share-based compensation tax benefits and the expiration of the Netherlands tax ruling in 2022 on future effective tax rates.